Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Pediatric Immune Response to Infectious Shock (PedIRIS)

9 novembre 2018 aggiornato da: Hospices Civils de Lyon

Infectious shocks are associated with high mortality rates (20-40%). Anti-inflammatory strategies based on the postulate that mortality related to sepsis is mainly due to an overwhelming pro-inflammatory immune response have failed. Some patients surviving this initial phase can develop immune dysfunctions because the compensatory mechanisms become deleterious when they persist over time. The persistence of immunosuppression at day 3 or 5 is independently associated with more nosocomial infections and higher mortality rate. The clinical and laboratory evidence for sepsis induced immunosuppression have been recently reviewed by Hotchkiss et al. Apoptosis-induced depletion of immune effector and blood studies from septic patients showed decreased production of pro-inflammatory cytokines, decreased HLA-DR expression, increased percentage of regulatory T cells, and increased production of programmed cell death (PD)-1. Some small positive phase 2 trials of biomarker guided immune enhancing agents granulocyte-macrophage colony stimulating factor (GM-CSF) and interferon γ (IFN γ) have been reported.

There are insufficient data showing that such an immunosuppression exists in children. Only one study performed in children with organ dysfunctions admitted to pediatric intensive care unit (PICU), showed that 34% of them developed immunosuppression. This study was performed on a heterogeneous population and immunological analyses were limited. Therefore, there is a crucial need of studies on septic patients with matched controls to provide more evidence that the same paradigm exists in children. The collaboration of laboratories with a high level of experience in this domain, and a clinical unit with a high potential of recruitment of children with severe infectious shock should allow us to perform the first prospective study specifically done in children with infectious shock.

The main hypothesis is that children with severe infectious shock developed sepsis-induced immunosuppression as shown in adults. This will be assessed by the expression of HLA-DR on monocytes' surface. We make the hypothesis that children who become immunosuppressed are more prone to develop secondary nosocomial infectious and stayed longer in PICU and in hospital.

Children aged from 1 month to 17 years, admitted to PICU at HFME Lyon-Bron are eligible if they have the criteria for severe sepsis or septic shock, defined by the "Surviving Sepsis Campaign 2012" or those of Toxic Shock Syndrome (TSS) (definitions of CDC - Center for Disease Control). An information leaflet will be issued to parents and children / adolescents and they will be informed of their right to object to the search. Are provided as part of this research:

  • Immunological measures (mHLA -DR) in three stages: in the first 48 hours, between D3/5 and D7/9. The volume of collected blood will not exceed 2.4 ml / kg.
  • The collection of nosocomial infections and status at D30 A control group of patients hospitalized for surgery without sepsis or toxic shock criteria will be recruited in the same hospital by ICU investigators and matched for age. Similarly controls will be given oral and written information and they will have the opportunity to deny inclusion. They will have the same exams as the first group of patients.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Effettivo)

105

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Lyon, Francia
        • Hospices Civils De Lyon

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 1 mese a 17 anni (Bambino)

Accetta volontari sani

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria Infectious shock group:

  • Children aged from 1 month to <18 years
  • Diagnosis of severe infectious shock at PICU or within the first 24 hours following PICU admission: severe sepsis or septic shock, defined by Surviving Sepsis Campaign 2012, or Toxic Shock Syndrome, defined by CDC criteria.

Inclusion Criteria Control group:

  • Healthy children aged matched to cases
  • Hospitalized for an elective surgery (dental, ENT, maxillofacial, urologic, hernia surgery, neurosurgery without massive hemorrhage)
  • Without any criteria of infection.

Exclusion Criteria (both groups):

  • Chronic inflammatory disease;
  • Immunodeficiency;
  • Long-term corticosteroids;
  • Ongoing immunosuppressive treatment;
  • Transplanted patients;
  • Tumors, hematological diseases;
  • No health insurance coverage;
  • Refusal to participate (from parents and/or patient) or inability to understand information.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Altro: Children with infectious shock
Children aged from 1 month to <18 years. In 3 stratified groups : <2 years, 2-8 years, and >8 years. About one third of the patients are expected in each age-group.
Altro: Control group: healthy children
Healthy children aged-matched to cases (same stratification group, about 20 per age group); They will be hospitalized for an elective surgery (dental, ENT, maxillofacial, urologic, hernia surgery, neurosurgery without massive hemorrhage) and without any infection.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
proportion of patients with a mHLA-DR level <30%
Lasso di tempo: up to Day 9
mHLA-DR is measured by flow cytometry
up to Day 9
proportion of patients with a mHLA-DR level significantly lower than healthy children.
Lasso di tempo: in the pre-operative period
mHLA-DR is measured by flow cytometry
in the pre-operative period

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
total lymphocytes
Lasso di tempo: Day 1
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
Day 1
total lymphocytes
Lasso di tempo: between Day 3 and day 5
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
between Day 3 and day 5
total lymphocytes
Lasso di tempo: between Day 7 and day 9
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
between Day 7 and day 9
levels of CD4+
Lasso di tempo: Day 1
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
Day 1
levels of CD4+
Lasso di tempo: between Day 3 and day 5
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
between Day 3 and day 5
levels of CD4+
Lasso di tempo: between Day 7 and day 9
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
between Day 7 and day 9
levels of CD25+
Lasso di tempo: day 1
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
day 1
levels of CD25+
Lasso di tempo: between Day 3 and day 5
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
between Day 3 and day 5
levels of CD25+
Lasso di tempo: between Day 7 and day 9
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
between Day 7 and day 9
levels of T lymphocytes (Treg)
Lasso di tempo: Day 1
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
Day 1
levels of T lymphocytes (Treg)
Lasso di tempo: between Day 3 and day 5
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
between Day 3 and day 5
levels of T lymphocytes (Treg)
Lasso di tempo: between Day 7 and day 9
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
between Day 7 and day 9
dosage of cytokines
Lasso di tempo: Day 1
Day 1
dosage of cytokines
Lasso di tempo: between Day 3 and day 5
between Day 3 and day 5
dosage of cytokines
Lasso di tempo: between Day 7 and day 9
between Day 7 and day 9
Number of nosocomial infections
Lasso di tempo: up to Day 30
up to Day 30
Type of nosocomial infections
Lasso di tempo: up to Day 30
bacteremia, ventilator-associated pneumonia, urinary tract infection, other sites.
up to Day 30
Mortality
Lasso di tempo: up to Day 30
up to Day 30
Length of vasoactive treatments
Lasso di tempo: up to Day 30
up to Day 30

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Etienne JAVOUHEY, Hospices Civils De Lyon

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

26 settembre 2014

Completamento primario (Effettivo)

4 agosto 2018

Completamento dello studio (Effettivo)

4 agosto 2018

Date di iscrizione allo studio

Primo inviato

21 luglio 2016

Primo inviato che soddisfa i criteri di controllo qualità

25 luglio 2016

Primo Inserito (Stima)

28 luglio 2016

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

14 novembre 2018

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2018

Ultimo verificato

1 novembre 2018

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 69HCL16_0478

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su campioni di sangue

3
Sottoscrivi